Treats relapsing forms of multiple sclerosis (MS). ANDA 209598, held by Hetero Labs Ltd V. Teriflunomide.
As of Nov 16, 2026, ANDA 209598 (Teriflunomide), held by Hetero Labs Ltd V, was first approved by FDA on Mar 13, 2023, with 1 approved supplement and 0 published complete response letters.
Teriflunomide tablets are indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Mar 13, 2023 | Original application | Approved | None posted |
| Teriflunomide7MG · tablet;oral | Teriflunomide | Rx |
| Teriflunomide14MG · tablet;oral | Teriflunomide | Rx |
| Jan 29, 2025 | Supplement 3Labeling · Standard review | Approved | None posted |
| Mar 13, 2023 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters